LADENBURG THALM/SH SH lowered shares of Zynex (NASDAQ:ZYXI – Free Report) from a buy rating to a neutral rating in a report released on Wednesday morning, MarketBeat.com reports. Separately, HC ...

Royal Bank of Canada cut shares of Zynex (NASDAQ:ZYXI – Free Report) from an outperform rating to a sector perform rating in a research report sent to investors on Wednesday, Marketbeat.com reports.

Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Fintel reports that on March 12, 2025, RBC Capital downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Outperform to ...

Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Despite a net loss and TRICARE payment suspension, Zynex Inc (ZYXI) shows resilience with revenue growth and strategic ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex, Inc. ( NASDAQ:ZYXI ) just released its latest full-year report and things are not looking great. It wasn't ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ICU Medical (ICUI – Research Report) and ...

Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.

--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors concerning the Company's possible violations of federal ...